You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

164 Results
Document
New
Jun 2025
Document
New
Jun 2025
Document
New
Jun 2025
Document
New
Jul 2025
Document
New
Jul 2025
Document
New
Jul 2025
Drug
Other Name(s): Reblozyl®
Quick Link(s): Drug Monograph, Patient Info Sheet
Jul 2025
Regimen
Cancer Type:
Hematologic, 
Myelodysplastic Syndrome (MDS)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    luspatercept - For the treatment of red-blood cell (RBC) transfusion-dependent anemia associated with Myelodysplastic Syndromes (MDS), according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
luspatercept
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jul 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
amivantamab (Unfunded),
lazertinib (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jul 2025

Pages